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Abstract. Colorectal cancer (CRC) is a notable cause of 
cancer-associated mortality worldwide, making it a pertinent 
topic for the study of cancer and its treatment. Staphylococcal 
enterotoxin B (SEB), an enterotoxin produced by 
Staphylococcus aureus, has been demonstrated to exert anti-
cancer and antimetastatic effects due to its ability to modify 
cell immunity and cellular signaling pathways. In the current 
study, SEB was investigated, including whether it exerts its 
growth inhibitory effects on colon adenocarcinoma cells. This 
may occur through the manipulation of a key tumor growth 
factor, termed transforming growth factor-β (TGF-β), and its 
signaling pathway transducer, Smad2/3. The human colon 
adenocarcinoma HCT116 cell line was treated with different 
concentrations of SEB, and cell number was measured using 
MTT assay at different treatment times. Smad2/3 RNA 
expression level was analyzed in untreated or SEB-treated 
cells using quantitative polymerase chain reaction, which 
indicated significant differences between cell viability and 
Smad2/3 expression levels. SEB effectively downregulated 
Smad2/3 expression in the HCT116 cells at concentrations 
of 1 and 2 µg/ml (P=0.0021 and P=0.0017, respectively). 
SEB concentrations that were effective at inhibiting Smad2/3 
expression were correlated with those able to inhibit the prolif-
eration of the cancer cells. SEB inhibited Smad2/3 expression 
at the mRNA level in a concentration- and time-dependent 
manner. The present study thus proposed SEB as an agent able 
to significantly reduce Smad2/3 expression in colon cancer 
cells, provoking moderate TGF-β growth signaling and the 
reduction of tumor cell proliferation.
Introduction
Colorectal cancer (CRC) is the second leading cause of 
cancer-associated mortality worldwide, according to the 
International Agency for Research on Cancer (1). Cancer 
reports reveal that ~1 million new cases of CRC were 
detected worldwide in 2008, establishing it as a key focus 
for the study of cancer and therapeutic approaches (1,2). 
In CRC and numerous other types of cancer, it has been 
established that the aberration of the growth factor signaling 
pathways can function in tumor initiation, progression and 
metastasis (3-6). Transforming growth factor β (TGF-β) 
has been identified as a key growth factor triggering varied 
biological processes, including proliferation, differentiation 
and programmed cell death (apoptosis). Studies indicate that 
this factor functions in signaling during the later stages of 
certain types of cancer and promotes tumor development, 
progression and metastasis (7,8). 
TGF-β binds heterodimeric receptor complexes of 
transmembrane serine/threonine kinases known as type I 
and type II receptors (TGβRI and TGβRII). Cell signaling 
triggers interaction of TGF-β with TGβRII, followed by 
TGβRI activation. Activated TGβRI initiates the recruit-
ment and phosphorylation of a family of signal transducers, 
termed Smad factors. A complex of phosphorylated Smad2 
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and Smad3 components associates with Smad4, and these 
translocate to the nucleus to activate the transcription of 
downstream target genes (7-9). 
It is well-established that growth factors with a broad range 
of cellular effects, such as TGF-β, must be subject to extensive 
regulation to control their expression and function. This regu-
lation includes mechanisms that occur during a diversity of 
growth events that are dependent on cell and tissue contexts; it 
may be apt, therefore, to utilize cell growth inhibition as a form 
of cancer therapy (8,9). Several reports have indicated that the 
targeting of TGF-β signaling during the late stages of carcino-
genesis may be a useful tool for the treatment of human cancer, 
including CRC, glioblastoma and breast cancer; repressing the 
function of the TGF-β signal transduction pathway compo-
nents may thus provide an effective therapeutic strategy for 
the treatment of CRC (9,10).
For hundreds of years, it has been reported that certain 
infectious diseases exert a beneficial, therapeutic effect upon 
malignancy (11-13). Bacteria and associated molecules have 
been utilized in diverse fields of cancer therapy, including 
their use as vectors for gene therapy, as carriers of tumoricidal 
agents and bacterial toxins have been used in tumor repression 
within their role of binding tumor surface antigens. Toxins 
are unique bacterial factors with a suggested protective role 
in carcinogenesis and in cancer remission (14-17). Previous 
studies have demonstrated that bacterial toxins may lead to 
the cytolysis and death of a range of malignant cells; in this 
regard, the bacterial toxin-based vaccine was widely used to 
successfully treat sarcomas, carcinomas, lymphomas, mela-
nomas and myelomas (13,14). There is evidence that certain 
types of bacterial toxins may aid the prevention or treatment 
of cancer; it is this that inspired the development of the earliest 
toxin-based cancer therapies (11-13).
Certain bacteria secrete enterotoxins able to modulate 
cellular signaling processes, controlling proliferation, 
apoptosis and differentiation during carcinogenesis (18-21). 
Although it has demonstrated successful results in vivo, further 
investigation into the targeting mechanisms of bacteria is 
required in order to develop a complete therapeutic approach 
for cancer treatment. Regarding the basic function of bacterial 
enterotoxins in tumor repression, it is rational to hypothesize 
that anticancer properties may partially be associated with 
their regulation of the cell signaling genes involved in cancer 
development and progression. However, modulation of a 
distinct signaling pathway to explain the possible inhibitory 
action of staphylococcal enterotoxins in cancer, including 
CRC, has yet to be elucidated.
Staphylococcal enterotoxins are a family of structur-
ally-related proteins produced by Staphylococcus aureus. 
Staphylococcal enterotoxin B (SEB) belongs to the superan-
tigen protein family. These are proteins or peptides produced 
by various microorganisms, including bacteria, mycoplasma 
or viruses, and induce T lymphocytes clonally (22-24). It 
has been demonstrated that SEB exerts anticancer and anti-
metastatic effects due to its ability to modify cell immunity 
processes and cancer cell signaling pathways (22,23). These 
promising characteristics prompted study into whether SEB 
reduces CRC cell proliferation. As bacterial enterotoxins have, 
to a certain extent, previously been harnessed for cancer treat-
ment (22-24), we hypothesized that the anticancer properties of 
the enterotoxin may be partially recapitulated by manipulating 
growth signaling pathways.
The aim of the present study was to investigate the growth 
inhibitory effect of SEB on CRC growth through the in vitro 
manipulation of the TGF-β signaling pathway transduction 
components Smad2/3, in vitro. The study was designed to 
provide an insight into the molecular mechanism of SEB in 
colon cancer cell signaling pathways, emphasizing the poten-
tial for novel toxin -based cancer therapies.
Materials and methods
Cell culture. HCT116, a human colorectal adenocarcinoma 
cell line from original tumors of pathological differentia-
tion grade II, was selected from a panel of CRC cell lines to 
examine the downstream effects of SEB on TGF-β.
The cell line was obtained from the National Cell Bank 
of Iran, affiliated to the Pasteur Institute (Tehran, Iran). The 
cells were grown in RPMI-1640 medium containing 25 mM 
D-glucose, 4 mM L-glutamine and 1 mM sodium pyruvate, 
supplemented with 5% (v/v) heat-inactivated fetal bovine serum 
(FBS), 2 mM GlutaMAX, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 250 ng/ml amphotericin (all Gibco; Thermo 
Fisher Scientific, Darmstadt, Germany) in 25-cm2 culture 
flasks (SPL Life Sciences, Pocheon, Korea). The cells were 
maintained at 37˚C in a humidified, 95% air/5% CO2 atmo-
sphere incubator in steady-state conditions. Cell viability was 
assessed using a trypan blue (Sigma-Aldrich, St. Louis, MO, 
USA) exclusion test and routinely demonstrated >95% viable 
cells in all flasks. 
SEB preparation. SEB (Sigma-Aldrich) was dissolved in 
distilled water according to the manufacturer's protocols. The 
enterotoxin was prepared as stock solutions of 20 µg/ml and 
stored at ‑20˚C until use.
MTT assay. To quantify cell proliferation, the in vitro growth 
inhibitory effect of SEB following incubation for 24, 48 or 72 h 
was measured using an MTT assay (Roche Applied Science, 
Mannheim, Germany). Monolayer cultures were trypsinized 
in the exponential growth phase and viable cell counts were 
assessed using trypan blue exclusion assay. The cells were then 
seeded in 96‑well flat‑bottom microtitration plates (SPL Life 
Sciences) at a density of 105 cells/well (200 µl media/well). 
After 24 h, upon reaching ~85% confluence, the cells were 
treated with different concentrations of SEB (0.5, 1 and 
2 µg/ml). In all in vitro experiments, untreated and distilled 
water‑treated cells were used as controls (with a final volume 
of 5 µl).
Following 24 h of drug application, for the recovery period, 
the cells were washed twice with fresh, FBS-free medium and 
the culture was continued (Fig. 1). This medium was then 
replaced with FBS-containing medium to remove unbound 
SEB.
Complete medium was replaced with 100 µl MTT after 
24, 48 and 72 h of treatment. The cells were incubated for 
3 h at 37˚C, and then 100 µl dimethyl sulfoxide was added 
to each well. The optical density (OD) was measured at 
a wavelength of 570 nm with background subtraction at 
630 nm using an ELX808 spectrophotometric microplate 
MOLECULAR MEDICINE REPORTS  13:  909-914,  2016 911
reader (BioTek Instruments, Inc., Winooski, VT, USA). Cell 
viability was calculated using the following formula: Cell 
viability (%) = (OD drug exposure / OD control) x 100.
Total RNA extraction from cells. Total RNA was extracted 
from the cultured HCT116 cells prior to or subsequent to 24, 
48 and 72 h of treatment with SEB. Total cellular RNA was 
extracted using TRIzol reagent (Invitrogen; Thermo Fisher 
Scientific, Karlsruhe, Germany) according to the manufac-
turer's protocols. Extracted total RNA was stored at ‑70˚C 
until use.
Gene expression analysis by reverse‑transcription quantita‑
tive polymerase chain reaction (RT‑qPCR). Smad2/3 gene 
expression level was analyzed by qPCR using the SYBR-Green 
method, with specific forward and reverse primers used to 
amplify the relevant genes (Table I) supplied by Genfanavaran 
(Tehran, Iran). GAPDH primers were used as an endogenous, 
positive control, and the data were normalized to the expres-
sion level of this housekeeping gene. This method included 
two steps as follows: i) RT-qPCR. RNA was transcribed to 
complementary DNA (cDNA) using the oligo(dT) procedure. 
Briefly, the cDNA was synthesized using total RNA and 
specific primers in a reverse transcription reaction. This reac-
tion was performed in a volume of 10 µl containing 1 µl total 
RNA, 1 µl 0.5 mM oligo(dT) RT primer, 1 µl 10 mM dNTP, 
1 µl reverse transcriptase and 6 µl reaction buffer. The reaction 
was incubated at 42˚C for 60 min, then terminated by heating 
at 85˚C for 5 min.
Subsequently, diluted cDNAs were amplified in a 20‑µl 
reaction containing SYBR-Green Master mix (Takara, Kyoto, 
Japan), forward and reverse Smad2/3‑specific primers (each 
1 µl) and diethylpyrocarbonate-treated distilled water, using 
35 cycles of PCR amplification under the following conditions: 
Denaturing at 95˚C for 1 min, annealing at 56˚C for 1 min and 
extension at 72˚C for 1 min. The PCR was performed on a 
CFX96 Touch Real-Time PCR Detection system (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA). 
All reactions were performed in triplicate. Specificity of 
primers was verified by observing a single peak dissociation 
curve for each run. The quantification cycle (Cq) was defined 
as the fractional cycle number at which the fluorescence passes 
the fixed threshold. Cq values were converted into total copy 
numbers using a standard curve. The absence of contami-
nation was verified using distilled water as non-template 
controls. PCR products were visualized by electrophoresis on 
a 2% agarose gel in TAE buffer using GelRed (Biotium, Inc., 
Hayward, CA, USA) (Fig. 2).
Statistical analysis. PCR data analysis was performed using 
the 2-∆∆cq method via GraphPad Prism 5.0 software (GraphPad 
Software, Inc., La Jolla, CA, USA). The mean, standard 
deviation, standard error of the mean and ranges of each 
parameter were calculated. A comparison was made of the 
mean and variance of gene expression using an analysis of 
variance (ANOVA). Significant differences were also deter-
mined (Prism) using ANOVA and Tukey's post-hoc test, or the 
unpaired Student's t-test, when applicable. P<0.05 was consid-
ered to indicate a statistically significant difference between 
data sets.
Results
SEB reduces the growth of the colon adenocarcinoma HCT116 
cell line. In order to test SEB antiproliferative activities, an 
MTT assay was used to evaluate the cell growth inhibitory 
effect upon altering duration and concentration of treatment. 
The results indicated that 1 and 2 µg/ml SEB significantly 
decreased HCT116 cell viability after 48 h of treatment 
(P=0.0021 and P=0.0017, respectively). It was concluded that 
SEB exerts its growth inhibitory effects in a concentration- and 
time-dependent manner. Overall, the data demonstrated that 
SEB was an effective inhibitor of human colon cancer cell 
proliferation (Fig. 3).
SEB downregulates Smad2/3 expression. The expression 
levels of TGF-β signaling targets Smad2 and -3 were evalu-
ated by qPCR. The results revealed that 1 and 2 µg/ml of SEB 
reduced Smad2/3 expression in the human colon adenocarci-
noma HCT116 cell line. SEB treatment at 2 µg/ml for 72 h 
significantly reduced Smad2 expression (P=0.006), while 
Smad3 expression was significantly reduced by SEB treatment 
at concentrations of 2 µg/ml for 48 h (P=0.0075), and at 1 and 
2 µg/ml for 72 h (P=0.011 and P=0.004, respectively). SEB 
reduced Smad2/3 expression in a dose- and time-dependent 
manner (Fig. 4). SEB inhibited the growth of HCT116 cells at 
high concentrations, which may be a partial consequence of 
the downregulation of TGF-β signaling pathway components.
It was predicted that SEB, as a potent inhibitor of colon 
cancer cell proliferation, would regulate the expression of key 
transducer genes controlling TGF-β cancer cell signaling. The 
SEB concentrations effective at inhibiting Smad2/3 expression 
were correlated with those used to inhibit the proliferation of 
the HCT116 cells. 
According to the data presented in the current study, 
Smad2/3 downregulation in the presence of SEB may precede 
Table I. Primer sequences used for quantitative polymerase 
chain reaction in the present study.
Target  Product
gene Primer sequence size, bp
Smad2  480
  Forward 5'-TCAAGCTTGAGTGTAAAC 
 CCTTACCACTATC-3'
  Reverse 5'-TAGCGGCCGCGAAAGCTA
 TGATTAACAG48GGG-3'
Smad3  340
  Forward 5'-TCAAGCTTGAACACCAGT 
 TCTACCTCCTG-3'
  Reverse 5'-TAGCGGCCGCGAAATGTC
 TCCCCGACGCGCTG-3
GAPDH  190
  Forward 5'-CGTTCCCAAAGTCCTCCT 
 GTTTC-3'
  Reverse 5'-TTTTTTTCCGCAGCCGCC
 TG-3'
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the inhibitory effects of SEB on proliferation; however, this 
proposal requires further empirical evaluation prior to trial as 
a CRC therapy.
Discussion
Malignancies such as CRC are currently considered an 
important area of study, due to the burden of the disease and 
the mortality rate (2-5). In numerous types of cancer, it has 
been established that aberration in genes encoding TGF-β 
signaling components can contribute to colon carcinogenesis 
in humans (7,8). This signaling pathway controls numerous 
cellular functions, including epithelial cell proliferation, apop-
tosis and migration, in addition to tumor initiation, progression 
and metastasis (8,9), making it a suitable target for cancer 
therapy (9,10). 
Bacterial toxins are widely studied for their anticancer 
activities and certain examples are currently in clinical devel-
opment, inciting anticipation for their pharmacological use in 
cancer treatment (15-17). These toxins can function to kill cells 
or alter cellular processes controlling proliferation, apoptosis 
and differentiation in carcinogenesis, and these salient roles 
have stimulated study into whether these may be useful anti-
cancer agents (14,15,17). Despite successful results in vivo, 
further investigation into the targeting mechanisms used 
  A
  B
  C
Figure 3. Cell viability of HCT116 after (A) 24, (B) 48 and (C) 72 h of SEB 
treatment. MTT assay results demonstrated that the duration of SEB treatment 
significantly inhibited the growth of the HCT116 cells at concentrations of 1 and 
2 µg/ml. *,**P<0.05. SEB, staphylococcal enterotoxin B; DW, distilled water.
Figure 1. HCT116 cell culture and treatment with SEB. HCT116 cells were cultured and treated with (A) 0.5, (B) 1 or (C) 2 µg/ml concentrations of SEB. 
(D) Untreated and (E) distilled water-treated cells were used as controls The cells were cultured as a monolayer in microtitration plates and cell morphology 
was evaluated microscopically after 48 h of SEB exposure (magnification, x400). SEB, staphylococcal enterotoxin B.
  A
  D
  C  B
  E
Figure 2. Gel electrophoresis of polymerase chain reaction (PCR) products. 
Smad 2, Smad 3 and GAPDH (positive control) PCR products were visual-
ized by agarose gel electrophoresis, via GelRed fluorescence. DW, distilled 
water.
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by bacteria are required to generate a complete therapeutic 
approach in cancer treatment. In several studies, however, the 
cancer-promoting signaling pathways instigated by bacterial 
toxins have been evaluated (19-21). 
SEB belongs to the family of superantigens. These proteins 
bind the β-chain of the T cell receptor and the major histocom-
patibility complex class II dimer (22,23). It has been suggested 
that SEB exerts anticancer and antimetastatic advantages 
via the modification of cancer signaling pathways and cell 
immunity (24). We therefore hypothesized that the anticancer 
functions of the enterotoxin may be partially due to changes to 
cancer signaling pathways. 
SEB, the potent inhibitor of colon cancer cell proliferation 
analyzed in the current study, was predicted to modulate the 
expression of key transducer genes controlling TGF-β cancer 
cell signaling. The present study aimed to provide an insight 
into this molecular mechanism, with an overall objective of 
promoting toxin use in CRC therapy and, potentially, other 
malignancies involving TGF-β signaling.
As previous studies implicated functionally active 
SEB-binding structures in mediating target cell killing in a 
range of human colon carcinoma cells (25), HCT116 cells were 
thus selected as a promising CRC model in the present study. 
It has also previously been demonstrated that these receptors 
are distinct from the conventional MHC class II molecules and 
bind to SEB in a class II-independent manner (25). 
Treatment of HCT116 cells at different concentrations for 
varying durations indicated that SEB treatment resulted in 
the time- and concentration-dependent inhibition of Smad2/3 
expression. The SEB inhibitory action upon Smad2/3 
expression occurred at concentrations as low as 1 µg/ml. It was 
presumed that this observable phenomenon resulted from the 
downregulated expression of TGF-β signaling components. 
SEB was more effective at reducing Smad3 expression than 
Smad2 expression (Fig. 2) and SEB was also demonstrated to 
exert an inhibitory effect on HCT116 cell proliferation subse-
quent to 48 h treatment at concentrations of 1 and 2 µg/ml 
(P=0.0021 and P=0.0017, respectively). The SEB concentra-
tions effective at inhibiting Smad2/3 expression correlated 
with those able to inhibit HCT116 cell proliferation. According 
to the data presented in the current study, it was hypothesized 
that Smad2/3 downregulation may precede the SEB inhibi-
tion of cell proliferation, but further evaluation is required to 
confirm this.
Results of the present study are consistent with those from 
previous studies, indicating that SEB exerts anti-angiogenic 
effects (22-24). In these studies, SEB was demonstrated to 
be effective at inducing apoptosis and attenuating cancer cell 
proliferation.
In accordance with the present study, a previous study 
revealed that SEB induced the Fas/Fas ligand-mediated cytol-
ysis of target cells (26), postulating that Fas/Fas ligand may be 
a key mediator for SEB-mediated cell death (26). In this regard, 
it should be noted that TGF-β also activates other downstream 
signaling pathways, including Rho GTPases, the extracellular 
signaling-regulated kinases, c-Jun NH2-terminals kinase and 
phosphatidylinositol-3 kinase (8-10), and it is probable that 
these pathways are also affected by enterotoxin activity. The 
use of SEB in the complete reduction of CRC proliferation, 
acting solely through Smad2/3 downregulation, therefore 
requires comprehensive examination.
Additionally, it has previously been reported that 
anthrax toxin (a dangerous bacterial toxin secreted by 
Bacillus anthracis) inhibits the growth of Ras-transformed 
cancerous cells by disturbing mitogen-activated protein kinase 
(MAPK) signaling pathways. It has therefore been suggested 
that this toxin may also be used against cancer cells in which 
MAPKs are activated by oncogenic proteins; this specificity 
ensures the selective damage of tumors at a low dosage (27). 
Furthermore, bacterial toxins may be used in targeted cancer 
therapy or synergistically potentiate the activity of anticancer 
drugs (28-30). It is therefore recommended that additional 
studies further analyze the synergistic activity of enterotoxin 
with anticancer drugs.
Although SEB is proposed to be an attractive biomol-
ecule in cancer treatment, a significant drawback of using the 
enterotoxin as an anticancer agent is its toxicity at the dose 
required for therapeutic efficacy. Furthermore, sufficient 
experimental evidence to justify the conclusion that SEB has 
therapeutic value in TGβRI/II-positive cancer cells is yet to be 
demonstrated.
In conclusion, identification of molecular mechanisms 
involved in beneficial functions of biotoxins to treat cancer 
may provide a novel insight into immunotoxin-based cancer 
therapy; further investigation and development in these studies 
may add a further dimensions to cancer treatment. Nonetheless, 
the successful translation of these approaches into scientific 
practice is likely to depend on the outcome of clinical trials. 
In the present study, SEB significantly reduced the 
expression of Smad2/3, which are components of the TGF-β 
Figure 4. SEB downregulates Smad2 and Smad3 expression Relative 
(A) Smad2 and (B) Smad3 gene expression, normalized against GAPDH 
levels. The HCT116 cells showed significantly reduced Smad2 and Smad3 
expression after 48 h of treatment with 1 and 2 µg/ml of SEB. *,**P<0.05. 
SEB, staphylococcal enterotoxin B; DW, distilled water.
  A
  B
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signaling pathway. It was further demonstrated that SEB may 
successfully suppress CRC proliferation, and that this suppres-
sion may be partially attributable to TGF-β signaling pathway 
inhibition. The continued examination of these salient molec-
ular features may yet facilitate the development of the effective 
immunotoxin-based therapy of malignancies.
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